Pharmacokinetic similarity study of levodopa/carbidopa [ND0612H] to Duodopa in healthy volunteers

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 09 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2017 According to NeuroDerm media release, based on minutes from a meeting held in January 2017 with the EMA and the preliminary results of trial 006 (CT profile 261957), company has modified its EU clinical and regulatory development path. The modified strategy will be based on restarted and amended iNDiGO trial (CT profile 252739), rather than on bioequivalent pharmacokinetic (PK) studies. Hence this study will not be carried out.
01 Mar 2017 Status changed from planning to discontinued, according to a NeuroDerm media release.
25 Aug 2016 According to a NeuroDerm media release, this trial is expected to initiate at the end of 2016 or beginning of 2017.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com